{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:23:29Z","timestamp":1772781809120,"version":"3.50.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":1476,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1111\/j.1524-4733.2009.00512.x","type":"journal-article","created":{"date-parts":[[2009,3,11]],"date-time":"2009-03-11T05:07:27Z","timestamp":1236748047000},"page":"697-707","source":"Crossref","is-referenced-by-count":26,"title":["Age-Based Programs for Vaccination against HPV"],"prefix":"10.1016","volume":"12","author":[{"given":"Elamin H.","family":"Elbasha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik J.","family":"Dasbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph P.","family":"Insinga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard M.","family":"Haupt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliav","family":"Barr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl.","key":"10.1111\/j.1524-4733.2009.00512.x_bib10","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.jcv.2004.12.008","article-title":"The epidemiology of human papillomavirus infections","volume":"32","author":"Baseman","year":"2005","journal-title":"J Clin Virol"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00007435-199017010-00004","article-title":"Prevalence, incidence, and estimated life-time risk of cervical human papillomavirus infections in a nonselected Finnish female population","volume":"17","author":"Syrjanen","year":"1990","journal-title":"Sex Transm Dis"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib30","first-page":"387","article-title":"Cancer and infection: estimates of the attributable fraction in 1990","volume":"6","author":"Pisani","year":"1997","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0002-9343(97)00177-0","article-title":"Epidemiology of genital human papillomavirus infection","volume":"102","author":"Koutsky","year":"1997","journal-title":"Am J Med"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib50","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1158\/1055-9965.EPI-04-0551","article-title":"Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review","volume":"14","author":"Kreimer","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib60","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1055-9965.EPI-04-0569","article-title":"Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening","volume":"14","author":"Bray","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib70","first-page":"701","article-title":"Cancer incidence and mortality trends among whites in the United States, 1947\u201384","volume":"79","author":"Devesa","year":"1987","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib80","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(04)16674-9","article-title":"The cervical cancer epidemic that screening has prevented","volume":"364","author":"Peto","year":"2004","journal-title":"Lancet"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib90","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1023\/A:1018435522475","article-title":"International incidence rates of invasive cervical cancer after introduction of cytological screening","volume":"8","author":"Gustafsson","year":"1997","journal-title":"Cancer Causes Control"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib100","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib110","author":"American Cancer Society"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib120","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa020586","article-title":"A controlled trial of a human papillomavirus type 16 vaccine","volume":"347","author":"Koutsky","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib130","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1016\/j.vaccine.2003.11.059","article-title":"Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine","volume":"22","author":"Brown","year":"2004","journal-title":"Vaccine"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib140","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib150","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1086\/428779","article-title":"A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica","volume":"191","author":"Castle","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib160","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1258\/0956462053420211","article-title":"Age-specific incidence and clearance of high-risk human papillomavirus infections in women in the former Soviet Union","volume":"16","author":"Syrjanen","year":"2005","journal-title":"Int J STD AIDS"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib170","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1086\/430275","article-title":"Human papillomavirus through the ages","volume":"191","author":"Winer","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib180","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1086\/507432","article-title":"Prevalence of HPV infection among men: a systematic review of the literature","volume":"194","author":"Dunne","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib190","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1046\/j.1524-4733.2001.45061.x","article-title":"Modeling for health care and other policy decisions: uses, roles, and validity","volume":"4","author":"Weinstein","year":"2001","journal-title":"Value Health"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib200","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3201\/eid1301.060438","article-title":"Model for assessing human papillomavirus (HPV) vaccination strategies","volume":"13","author":"Elbasha","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib210","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/epirev\/mxj006","article-title":"Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease","volume":"28","author":"Dasbach","year":"2006","journal-title":"Epidemiol Rev"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib220","series-title":"Vaccines for the 21st Century: A Tool for Decisionmaking. Appendix 11. Human Papillomavirus","first-page":"213","author":"Institute of Medicine (U.S.). Committee to Study Priorities for Vaccine Development","year":"2000"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib230","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3201\/eid0901.020168","article-title":"Cost effectiveness of a potential vaccine for human papillomavirus","volume":"9","author":"Sanders","year":"2003","journal-title":"Emerg Infect Dis"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib240","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.290.6.781","article-title":"Potential health and economic impact of adding a human papillomavirus vaccine to screening programs","volume":"290","author":"Kulasingam","year":"2003","journal-title":"JAMA"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib250","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/ijc.11334","article-title":"A comprehensive natural history model of human papillomavirus (HPV) infection and cervical cancer: potential impact of and HPV 16\/18 vaccine","volume":"106","author":"Goldie","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib260","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/jnci\/djh104","article-title":"Projected clinical benefits and cost-effectiveness of a human papillomavirus 16\/18 vaccine","volume":"96","author":"Goldie","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib270","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.3201\/eid1011.040222","article-title":"Evaluating human papillomavirus vaccination programs","volume":"10","author":"Taira","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib280","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3201\/eid1402.070499","article-title":"Cost-effectiveness of human papillomavirus vaccination in the United States","volume":"14","author":"Chesson","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib290","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/0272989X02239651","article-title":"Economic evaluation of vaccination programs: the impact of herd immunity","volume":"23","author":"Brisson","year":"2003","journal-title":"Med Decis Making"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib300","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/oxfordjournals.aje.a114471","article-title":"Individual versus public priorities in the determination of optimal vaccination policies","volume":"124","author":"Fine","year":"1986","journal-title":"Am J Epidemiol"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib310","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0047-2727(91)90048-7","article-title":"Externalities and compulsory vaccinations","volume":"45","author":"Brito","year":"1991","journal-title":"J Public Econ"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib320","first-page":"222","article-title":"Disease eradication: private versus public vaccination","volume":"87","author":"Geoffard","year":"1997","journal-title":"Am Econ Rev"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib330","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/01.olq.0000161181.48687.cf","article-title":"Costs and effects of chlamydial screening: dynamic versus static modeling","volume":"32","author":"Welte","year":"2005","journal-title":"Sex Transm Dis"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib340","first-page":"1","article-title":"Sexual activity and contraceptive practices among teenagers in the United States, 1988 and 1995. National Center for Health Statistics","volume":"23","author":"Abma","year":"2001","journal-title":"Vital Health Stat"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib350","first-page":"Q1","article-title":"Recommended childhood and adolescent immunization schedule\u2014United States, 2006","volume":"54","author":"CDC","year":"2006","journal-title":"MMWR"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib360","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1158\/1055-9965.355.13.3","article-title":"Pap screening in a U.S. health plan","volume":"13","author":"Insinga","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib370","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ypmed.2004.03.035","article-title":"Cervical cancer screening among U.S. women: analyses of the 2000 National Health Interview Survey","volume":"39","author":"Hewitt","year":"2004","journal-title":"Prev Med"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib380","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1136\/jech.2005.041020","article-title":"Effect of area poverty rate on cancer screening across US communities","volume":"60","author":"Schootman","year":"2006","journal-title":"J Epidemiol Community Health"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib390","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/sj.bjc.6602728","article-title":"The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13,842 women","volume":"93","author":"Bigras","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib400","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1136\/bmj.326.7392.733","article-title":"Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening","volume":"326","author":"Coste","year":"2003","journal-title":"BMJ"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib410","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"The FUTURE II Study Group","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib420","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Females United to Unilaterally Reduce Endo\/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib430","series-title":"Statistical Abstracts of the United States: Consumer Price Index","author":"US Bureau of Labor Statistics","year":"2002"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib440","series-title":"MarketScan\u00ae Database","author":"Medstat","year":"2001"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib450","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1001\/jama.287.18.2382","article-title":"Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance","volume":"287","author":"Kim","year":"2002","journal-title":"JAMA"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib460","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1086\/375074","article-title":"The health and economic burden of genital warts in a set of private U.S. health plans","volume":"36","author":"Insinga","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib470","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00005650-199806000-00002","article-title":"Toward consistency in cost-utilities analysis","volume":"36","author":"Gold","year":"1998","journal-title":"Med Care"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib480","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/0272989X07302128","article-title":"Abnormal outcomes following cervical cancer screening: event duration and health utility loss","volume":"27","author":"Insinga","year":"2007","journal-title":"Med Decis Making"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib490","unstructured":"Myers E, Green S, Lipkus I. 2004; Patient preferences for health states related to HPV infection: visual analogue scales vs. time trade-off elicitation. Proceedings of the 21st International Papillomavirus Conference, Abstract No. 390.2 2004. Mexico City, Mexico."},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib500","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1524-4733.2003.00234.x","article-title":"Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices\u2014modeling studies","volume":"6","author":"Weinstein","year":"2003","journal-title":"Value Health"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib510","series-title":"Cost-Effectiveness in Health and Medicine. Report of the Panel on Cost-Effectiveness in Health and Medicine","author":"Gold","year":"1996"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib520","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ajog.2004.01.043","article-title":"Diagnoses and outcomes in cervical cancer screening: a population-based study","volume":"191","author":"Insinga","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib530","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/(SICI)1097-0215(19970410)71:2<159::AID-IJC6>3.0.CO;2-#","article-title":"International incidence rates of invasive cervical cancer before cytological screening","volume":"71","author":"Gustafsson","year":"1997","journal-title":"Int J Cancer"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib540","author":"Surveillance, Epidemiology, and End Results (SEER) Program"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib550","first-page":"503","article-title":"Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada","volume":"163","author":"Sellors","year":"2000","journal-title":"CMAJ"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib560","series-title":"Infectious Diseases of Humans: Dynamics and Control","author":"Anderson","year":"1991"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib570","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1137\/S0036144500371907","article-title":"The mathematics of infectious diseases","volume":"42","author":"Hethcote","year":"2000","journal-title":"SIAM Rev"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib580","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1002\/(SICI)1097-0258(19991215)18:23<3263::AID-SIM315>3.0.CO;2-3","article-title":"Evaluating the cost-effectiveness of vaccination programmes: a dynamic approach","volume":"18","author":"Edmunds","year":"1999","journal-title":"Stat Med"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib590","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00001648-200211000-00006","article-title":"The theoretical population level impact of a prophylactic human papilloma virus vaccine","volume":"13","author":"Hughes","year":"2002","journal-title":"Epidemiology"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib600","series-title":"The Clinical Handbook of Human Papillomavirus","article-title":"The potential public health impact of vaccines against human papillomavirus","author":"Barnabas","year":"2004"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib610","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.mbs.2005.05.004","article-title":"Vaccination against multiple HPV types","volume":"197","author":"Elbasha","year":"2005","journal-title":"Math Biosci"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib620","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1371\/journal.pmed.0030138","article-title":"Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modeling analyses","volume":"3","author":"Barnabas","year":"2006","journal-title":"PLoS Med"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib630","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/bmj.38737.607558.80","article-title":"Is everything in health care cost-effective? Bias in published cost-effectiveness studies","volume":"332","author":"Bell","year":"2006","journal-title":"BMJ"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib640","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1016\/j.vaccine.2007.04.086","article-title":"The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada","volume":"25","author":"Brisson","year":"2007","journal-title":"Vaccine"},{"key":"10.1111\/j.1524-4733.2009.00512.x_bib650","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/hec.985","article-title":"Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra","volume":"14","author":"Claxton","year":"2005","journal-title":"Health Econ"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301510607310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301510607310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T10:06:49Z","timestamp":1684922809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301510607310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S1098301510607310"],"URL":"https:\/\/doi.org\/10.1111\/j.1524-4733.2009.00512.x","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}